Clinical Research Directory
Browse clinical research sites, groups, and studies.
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
Sponsor: M.D. Anderson Cancer Center
Summary
This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.
Official title: Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1000
Start Date
2019-11-22
Completion Date
2025-12-31
Last Updated
2025-11-13
Healthy Volunteers
No
Conditions
Interventions
Biospecimen Collection
Undergo collection of blood and tissue samples
Electronic Health Record Review
Review of medical records
Locations (10)
Banner - MD Anderson Cancer Center
Gilbert, Arizona, United States
Baptist- MD Anderson Cancer Center
Jacksonville, Florida, United States
The Queen's Medical Center
Honolulu, Hawaii, United States
St. Luke's Cancer Institute
Boise, Idaho, United States
Cooper Hospital UNIV MED CTR.
Camden, New Jersey, United States
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, United States
Houston Methodist Cancer Center
Houston, Texas, United States
M D Anderson Cancer Center
Houston, Texas, United States
UT Health San Antonio MD Anderson Cancer Center
San Antonio, Texas, United States
Baylor Scott & White Research Institute
Temple, Texas, United States